Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 7, 2014; 20(1): 235-241
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.235
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.235
Table 1 Patients’ general characteristics n (%)
Numbers | |
Age (range), yr | 531 (36-71) |
Sex | |
Male | 25 (81) |
Female | 6 (19) |
Etiology | |
HBV | 26 (83.9) |
HCV | 1 (3.2) |
Others | 4 (12.9) |
Status of primary liver mass | |
Stable | 13 (41.9) |
Progressive | 18 (58.1) |
Metastatic sites | |
Lung | 28 (90.3) |
Lymph node | 10 (32.3) |
Bone | 8 (25.1) |
Peritoneum | 3 (9.7) |
Previous treatment before sorafenib | |
TACE | 29 (93.5) |
Surgery | 17 (54.8) |
Radiation | 12 (38.7) |
Hepatic arterial infusion | 9 (29.0) |
Radiofrequency ablation | 5 (16.1) |
- Citation: Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA. Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol 2014; 20(1): 235-241
- URL: https://www.wjgnet.com/1007-9327/full/v20/i1/235.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i1.235